OTCMKTS:IPSEY Ipsen (IPSEY) Stock Forecast, Price & News $34.00 0.00 (0.00%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$34.00▼$34.0050-Day Range$29.53▼$34.3452-Week Range$21.35▼$34.34Volume187 shsAverage Volume281 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.68%Price Target$30.60 ProfileProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort Interest Ipsen MarketRank™ ForecastAnalyst RatingHold2.38 Rating ScoreUpside/Downside10.0% Downside$30.60 Price TargetShort InterestHealthyDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.57Based on 2 Articles This WeekInsider TradingN/AProj. Earnings Growth10.36%From $2.51 to $2.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 stars 1.2 Analyst's Opinion Consensus RatingIpsen has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.60, Ipsen has a forecasted downside of 10.0% from its current price of $34.00.Amount of Analyst CoverageIpsen has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverIpsen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ipsen has recently decreased by 50.00%, indicating that investor sentiment is improving significantly. Previous Next 0.8 Dividend Strength Dividend YieldIpsen has a dividend yield of 0.68%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthIpsen does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Ipsen will have a dividend payout ratio of 8.30% next year. This indicates that Ipsen will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSEY. Previous Next 2.5 News and Social Media Coverage News SentimentIpsen has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ipsen this week, compared to 1 article on an average week. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ipsen insiders have not sold or bought any company stock. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ipsen are expected to grow by 10.36% in the coming year, from $2.51 to $2.77 per share.Price to Book Value per Share RatioIpsen has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ipsen (OTCMKTS:IPSEY) StockIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.Read More IPSEY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IPSEY Stock News HeadlinesSeptember 17, 2023 | msn.comIpsen celebrates 75 years of its location in Cherry ValleySeptember 15, 2023 | americanbankingnews.comIpsen S.A. (OTCMKTS:IPSEY) Receives $30.60 Average Target Price from BrokeragesSeptember 21, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>September 13, 2023 | americanbankingnews.comIpsen (OTCMKTS:IPSEY) Upgraded to Buy at UBS GroupSeptember 12, 2023 | americanbankingnews.comIpsen (OTCMKTS:IPSEY) Shares Pass Above 200-Day Moving Average of $30.01September 1, 2023 | finance.yahoo.comIpsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle HuguetAugust 21, 2023 | msn.comExelixis lead product hits main goal in Phase 3 prostate cancer trialAugust 17, 2023 | msn.comUS FDA approves French drugmaker Ipsen's rare bone disorder drugSeptember 21, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.August 16, 2023 | bloomberg.comUS Approves Ipsen’s Therapy for Rare Bone DiseaseAugust 16, 2023 | usnews.comUS FDA Approves Ipsen's Rare Bone Disorder DrugAugust 16, 2023 | finance.yahoo.comUS FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressivaJuly 28, 2023 | finanznachrichten.deIpsen Pharma: Ipsen delivers solid H1 2023 results and upgrades its full-year guidanceJuly 27, 2023 | marketwatch.comIpsen Shares Rise After It Upgrades 2023 OutlookJuly 27, 2023 | finance.yahoo.comIpsen delivers solid H1 2023 results and upgrades its full-year guidanceJuly 24, 2023 | finance.yahoo.comIpsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023July 21, 2023 | marketwatch.comIpsen's Bylvay for Alagille Syndrome Recommended for Approval by EU AgencyJuly 21, 2023 | finance.yahoo.comIpsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndromeJuly 19, 2023 | finanznachrichten.deIpsen Pharma: Ipsen announces European Commission decision on palovarotene for the treatment of FOPJuly 19, 2023 | uk.finance.yahoo.comIpsen announces European Commission decision on palovarotene for the treatment of FOPJune 30, 2023 | markets.businessinsider.comGenfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-ClassJune 30, 2023 | msn.comIpsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis PatientsJune 29, 2023 | finanznachrichten.deIpsen Pharma: Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressivaJune 29, 2023 | markets.businessinsider.comFDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone DiseaseJune 29, 2023 | finance.yahoo.comIpsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressivaJune 28, 2023 | bloomberg.comIpsen Gets FDA Advisers’ Backing for Rare Bone Disease TherapyJune 14, 2023 | msn.comMirum falls as FDA expands label for Ipsen’s liver disease therapySee More Headlines Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Company Calendar Ex-Dividend for 6/27 Dividend6/02/2023Dividend Payable6/27/2023Today9/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.60 High Stock Price Forecast$30.60 Low Stock Price Forecast$30.60 Forecasted Upside/Downside-10.0%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.58 Sales & Book Value Annual Sales$3.33 billion Price / SalesN/A Cash Flow$3.51 per share Price / Cash Flow9.68 Book Value$9.72 per share Price / Book3.50Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.98 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. David Loew (Age 56)MD, CEO & Director Comp: $2.38MMr. Aymeric Le Chatelier (Age 54)Exec. VP & Group CFO Dr. Aidan Murphy Ph.D. (Age 57)Exec. VP of Technical Operations Mr. Craig MarksVice-Pres of Investor RelationsMr. Francois Garnier (Age 61)Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer Ms. Gwenan WhiteExec. VP of Communications, Public Affairs & SustainabilityMr. Regis Mulot (Age 57)Exec. VP & Chief HR Officer Ms. Dominique Bery (Age 52)Head of Nordics & Baltics Dr. Yan Moore M.D. (Age 56)Sr. VP & Head of Oncology Therapeutic Area Dr. Alexander McEwanVice-Pres & Head of RadiopharmaceuticalsMore ExecutivesKey CompetitorsARCA biopharmaNASDAQ:ABIOBG MedicineOTCMKTS:BGMDGlobal WholeHealth PartnersOTCMKTS:GWHPHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQView All Competitors IPSEY Stock - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares. View IPSEY analyst ratings or view top-rated stocks. What is Ipsen's stock price forecast for 2023? 8 Wall Street analysts have issued 12 month target prices for Ipsen's stock. Their IPSEY share price forecasts range from $30.60 to $30.60. On average, they anticipate the company's share price to reach $30.60 in the next year. This suggests that the stock has a possible downside of 10.0%. View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts. How have IPSEY shares performed in 2023? Ipsen's stock was trading at $26.88 at the beginning of the year. Since then, IPSEY shares have increased by 26.5% and is now trading at $34.00. View the best growth stocks for 2023 here. Are investors shorting Ipsen? Ipsen saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 100 shares, a decrease of 50.0% from the August 15th total of 200 shares. Based on an average daily volume of 800 shares, the short-interest ratio is presently 0.1 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen announced a dividend on Thursday, June 1st. Stockholders of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.68%. Read our dividend analysis for IPSEY. What is Ipsen's stock symbol? Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY." How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ipsen's stock price today? One share of IPSEY stock can currently be purchased for approximately $34.00. How many employees does Ipsen have? The company employs 5,300 workers across the globe. How can I contact Ipsen? Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01. This page (OTCMKTS:IPSEY) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.